|View printer-friendly version|
Cidara Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Corporate Update
Fourth Quarter 2015 and Subsequent Highlights
- Announced Positive Data from Single and Multiple Dose Phase 1 Clinical Trials of CD101 IV; on track to initiate a Phase 2 Candidemia trial in 1H 2016: Cidara announced positive data from its Phase 1 single ascending dose and multiple ascending dose clinical trials of its antifungal drug candidate, CD101 IV, in healthy volunteers. Key results of the trials for CD101 IV reinforce the compound’s excellent safety and tolerability: CD101 IV was well tolerated across the entire dose range; no serious or severe adverse events were seen. In addition, the results support the ability of CD101 IV to be dosed once-weekly. Based on the results from the single and multiple ascending dose studies, in the first half of 2016 Cidara plans to initiate a multi-national comparative Phase 2 trial of once-weekly CD101 IV for the treatment of candidemia.
- Received Orphan Drug Designation for CD101 IV in Candidemia and Invasive Candidasis: Cidara announced that the
U.S. Food and Drug Administration( FDA) has granted orphan drug designation to CD101 IV for the treatment of candidemia and invasive candidiasis. Orphan drug designation provides eligibility for seven years of market exclusivity in the United Statesupon FDAapproval, a waiver from payment of user fees, an exemption from performing clinical studies in pediatric patients, and tax credits for the cost of the clinical research.
Progressto Initiate a Phase 2 Clinical Trial of CD101 Topical: Cidara reiterates its plans to commence a Phase 2 comparative clinical trial in VVC with CD101 topical by mid-2016.
“Cidara continued to execute its corporate strategy in the fourth quarter,” said
Fourth Quarter and Full Year 2015 Financial Results
- Cash, cash equivalents and short term investments totaled
$107.5 millionas of December 31, 2015, compared with $114.4 millionas of September 30, 2015and $22.8 millionas of December 312014.
- Research and development expenses were
$7.6 millionand $23.5 millionfor the three months and full year ended December 31, 2015, respectively, compared to $3.5 millionand $6.7 millionfor the same periods in 2014. The increases were primarily attributable to development activities for our two product candidates, CD101 IV and CD101 topical, which included the single and multiple ascending dose Phase 1 clinical trials for CD101 IV.
- General and administrative expenses were
$2.4 millionand $8.8 millionfor the three months and full year ended December 31, 2015, respectively, compared to $1.2 millionand $3.3 millionfor the same periods in 2014. The increases resulted primarily from personnel-related costs to support the growth of our operating activities as well as the costs associated with being a public company.
- Net loss for the three months ended
December 31, 2015was $9.9 million, compared to a net loss of $4.6 millionfor the fourth quarter of 2014. For the full year ended December 31, 2015, the net loss was $32.2 million, compared to $11.9 millionfor the comparable period in 2014.
- As of
February 29, 2016, Cidara had 13,822,747 common shares outstanding.
Cidara is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel anti-infectives for the treatment of diseases that are inadequately addressed by current standard-of-care therapies. Cidara's initial product portfolio comprises two formulations of the company's novel echinocandin, CD101. CD101 IV is a long-acting therapy for the treatment and prevention of serious, invasive fungal infections. CD101 topical is for the treatment of vulvovaginal candidiasis (VVC) and recurrent VVC (RVVC), a prevalent mucosal infection. In addition, Cidara has developed a proprietary immunotherapy platform, Cloudbreak™, designed to create compounds that direct a patient's immune cells to attack and eliminate pathogens that cause infectious disease. Cidara is headquartered in
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the effectiveness, safety, long-acting nature, anticipated human dosing and other attributes of CD101 IV, its potential to treat infections, the incidence of fungal infections, and the timing of clinical trials for CD101 IV and CD101 topical. Risks that contribute to the uncertain nature of the forward-looking statements include: the success and timing of Cidara’s preclinical studies and clinical trials; regulatory developments in
|Cidara Therapeutics, Inc.|
|Condensed Balance Sheets|
|Cash, cash equivalents, and short-term investments||$||107,514||$||22,796|
|Other current assets||704||217|
|LIABILITIES, CONVERTIBLE PREFERRED STOCK, AND STOCKHOLDERS' EQUITY (DEFICIT)|
|Series A convertible preferred stock||-||32,548|
|Stockholders' equity (deficit)||103,912||(11,445||)|
|Total liabilities, convertible preferred stock, and stockholders' equity (deficit)||$||109,974||$||24,350|
|Cidara Therapeutics, Inc.|
|Condensed Statements of Operations|
|Three months ended
|(In thousands, except share and per share data)||(unaudited)||(unaudited)|
|Research and development||$||7,564||$||3,474||$||23,475||$||6,710|
|Cost of in-process research and development acquired||-||-||-||1,607|
|General and administrative||2,364||1,175||8,838||3,306|
|Total operating expenses||9,928||4,649||32,313||11,623|
|Loss from operations||(9,928||)||(4,649||)||(32,313||)||(11,623||)|
|Other income (expense):|
|Interest income (expense), net||60||-||120||(88||)|
|Change in fair value of convertible notes payable||-||-||-||(183||)|
|Total other income (expense)||60||-||120||(271||)|
|Basic and diluted net loss per share||$||(0.72||)||$||(4.13||)||$||(3.25||)||$||(14.51||)|
|Shares used to compute basic and diluted net loss per share||13,731,519||1,126,707||9,920,382||819,868|
Robert H. Uhl Westwicke Partners, LLCManaging Director (858) 356-5932 email@example.com MEDIA CONTACT: Mike Beyer Sam Brown Inc.(312) 961-2502 firstname.lastname@example.org